The Building Blocks of CAR T-cell Clinical Trials

Panelists set up for addressing the clinical trial landscape, key challenges, regulations, and the future of cell and gene therapy.

Understanding how pharmaceutical companies can navigate regulatory oversight through streamlined techniques and logistical planning.

Proper planning can assist in the institutional biosafety committee (IBC) review process when preparing for CAR T-cell clinical trials.

Examining hurdles surrounding FDA approval and how to streamline the process

Transferring knowledge and continuing to work together with regulatory agencies will lead to changes in approval going forward.

How the right site can set up for a successful clinical trial for CAR T-cell therapy.

Effective strategies for fostering strong communication and teamwork with a clinical trial site.

Obtaining the right patient population for a CAR T-cell clinical trial is based off several factors from both the patient and the site.

Delivering the same safe product to a patient while improving timelines of clinical trials

The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.